RAC1 P29S

CI-VAR-00003333Explore in graph →ENST00000356142.4:c.85C>TClinVar 376362 CIViC 367

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Cutaneous Melanoma1
RAC1 P29S	PLX4720	Predictive	D	Supports Resistance	4	submitted	EID8056 In vitro and in vivo studies that demonstrate that RAC1-P29S is capable of promoting cell survival and resistance to treatment, specifically BRAF inhibition. The authors expressed both a 4-hydroxytamo… (full text at CIViC) PMID 31257073 · Lionarons et al., 2019 · Open in CIViC	civic
Melanoma2
RAC1 P29S	Dabrafenib + VemurafenibSubstitutes	Predictive	B	Supports Resistance	3	submitted	EID7669 In a retrospective study, resistance mechanisms to BRAF inhibitor such as vemurafenib or dabrafenib in patients with BRAF V600 mutated melanoma were evaluated. Among the 14 patients exhibiting early d… (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.